Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RadVax: Ipilimumab and Nivolumab With or Without HFRT in Metastatic Melanoma
NCT03646617Phase 2Active, not recruiting
- Sponsor
- Abramson Cancer Center
- Start
- Nov 2018
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and ipilimumab in melanoma (2 arms), sponsored by Abramson Cancer Center. Primary endpoint: Number of Adverse Events at 3.5 years. Started Nov 2018; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03646617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03646617.